Innoviva Income from Discontinued Operations 2010-2024 | INVA

Innoviva income from discontinued operations from 2010 to 2024. Income from discontinued operations can be defined as income or loss from the complete discontinuation of a segment or business, net of associated taxes and fees.
Innoviva Annual Income from Discontinued Operations
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $-95
2013 $-140
2012 $12
2011 $
2010 $
2009 $
Innoviva Quarterly Income from Discontinued Operations
(Millions of US $)
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30 $-43
2014-03-31 $-52
2013-12-31 $-68
2013-09-30 $-38
2013-06-30 $-35
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.241B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $868.423B 100.52
Novo Nordisk (NVO) Denmark $525.939B 40.14
Johnson & Johnson (JNJ) United States $384.413B 15.24
AbbVie (ABBV) United States $340.922B 18.04
Merck (MRK) United States $274.860B 16.67
AstraZeneca (AZN) United Kingdom $238.341B 21.24
Novartis AG (NVS) Switzerland $232.546B 16.16
Pfizer (PFE) United States $165.354B 21.61
Sanofi (SNY) $139.184B 13.15